News | July 29, 2025
Astec LifeSciences Q1 FY26 revenue up 30.3%
The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year
The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year
Upgrades 2025 full-year CDMO sales and margin outlook
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
Strengthening capabilities in Peptide Therapeutics and CDMO services
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Subscribe To Our Newsletter & Stay Updated
